No, this is not a Burning Man offshoot but in fact a serious gathering of more than 2,600 doctors, professors, health-industry professionals and psychedelic experts from around the world.
Psychedelic Science 2017 is a six-day international gathering featuring more than 100 presentations on the therapeutic uses of psychedelics, the neuroscience behind this research, the spread of psychedelic culture into the mainstream and much more.
The conference, which runs from April 19-24, is co-hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS) and the UK-based Beckley Foundation.
Per the Psychedelic Science 2017 website, in addition to discussing the process of legally positioning psychedelics into the medical field, attendees will share information on how plant medicine, LSD, ketamine, MDMA and marijuana show promise in the treatment of post-traumatic stress disorder, depression and a wide range of other mental and physical illnesses.
MAPS, founded in 1986, is a research and educational organization that develops medical, legal and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
The San Francisco-based non-profit believes opportunities in the area of psychedelic science and medicine are growing. It is leading the way in one of those areas.
MAPS predicts that the U.S. Food and Drug Administration (FDA) will approve MDMA-assisted psychotherapy as a legal treatment for post-traumatic stress disorder (PTSD) as soon as 2021.
“There have been a lot of these pilot studies, but for PTSD and depression, we have enough data and we’re moving into negotiations with the regulatory agencies,” Dr. Rick Doblin, executive director of MAPS, told SF Weekly.
“We have approval for MDMA for PTSD. What that means is that the path to prescription approval has now begun, and we are now starting FDA approval for use of psychedelic therapy by prescription. We’re currently estimating 2021 for FDA approval of MDMA,” said Doblin.
A growing body of research suggests that MDMA and other psychedelic drugs can be effective treatment for ailments ranging from post-traumatic stress disorder to social anxiety in autistic adults.
To that end, MAPS is undertaking a roughly $25 million plan to further its MDMA research. It is currently the only organization in the world that is funding clinical trials of MDMA-assisted psychotherapy.
Although the Psychedelic Science 2017 is sold out, every presentation will be available for free on the MAPS website the week after the conference.
California Governor Signs Several Marijuana-Related Bills
Bill Would Remove Cannabis Possession As Grounds For Deportation
FBI Investigating Possible Public Corruption In Sacramento’s Cannabis Industry
Compassion Lives on in California as Governor Signs The Dennis Peron and Brownie Mary Act
News6 days ago
Judge Says Police Seizure Of 900 Pounds Of Marijuana Was Illegal
Business5 days ago
California Company Develops Metal-Free Vape Cartridge
News5 days ago
Texas Suddenly Stops Issuing Permits For New Medical Marijuana Dispensaries
Grow6 days ago
Dear Danko: Expert Grow Advice
Movies4 days ago
Fantastic Fungi Is A New Documentary That Celebrates The World Of Mushrooms
News7 days ago
Cannabis Advocacy Groups Bring 51-foot Inflated Joint To Congress
News7 days ago
California Medical Marijuana Bills Await Governor’s Signature
News6 days ago
Mexican President Says State-Led Cannabis Legalization “Not On Our Agenda”